Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March ...
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
company developing universally implantable, bioengineered human tissues at commercial scale, today announced it will host an in-person and virtual investor event in New York on Thursday, March 6, 2025 at 12:00 PM ET. To register as an in-person or virtual attendee, please click here. The event will feature vascular surgery key opinion leaders (KOLs) Michael Curi, MD, MPA (Rutgers New Jersey Medical School) and Sammy Siada, DO, FACS, RPVI (UCSF Fresno), who will join company management to discuss the commercial plans and early market-launch success of Symvess (acellular tissue engineered vessel-tyod) for extremity arterial injury. Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair. The U.S. Food and Drug Administration (FDA) granted a full approval for Symvess in December 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue CapitalGlobeNewswire
- Humacyte (NASDAQ:HUMA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=HUMA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fMarketBeat
- Humacyte (HUMA): Benchmark Remains Bullish on Stock [Yahoo! Finance]Yahoo! Finance
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
HUMA
Earnings
- 11/12/25 - Beat
HUMA
Sec Filings
- 12/15/25 - Form 8-K
- 12/15/25 - Form 8-K
- 12/15/25 - Form 424B3
- HUMA's page on the SEC website